The mechanism which prevents lethal bacteria, streptococcus pneumoniae, from causing invasive disease is revealed. An important development in understanding how the bacterium that causes pneumonia, meningitis and septicaemia remains harmlessly in the nose and throat has been discovered at the University of Liverpool.
Streptococcus pneumoniae is a ‘commensal’, which can live harmlessly in the nasopharynx as part of the body’s natural bacterial flora. However, in the very young and old it can invade the rest of the body, leading to serious diseases such as pneumonia, sepsis and meningitis, which claim up to a million lives every year worldwide. However, the conditions that drive this bacterium from harmless commensal to major pathogen are not understood.
Scientists at the University have now uncovered the mechanisms by which this occurs and how it is regulated by the host immune system. They found that a specialised group of white blood cells called T regulatory cells are activated by the pneumococcus and move to dampen down a damaging pro-inflammatory response from the host immune system. When white blood cells attack bacteria they cause inflammation and, if this inflammation is uncontrolled it can become excessive and damage host tissues, allowing the bacteria to spread into the rest of the respiratory system and other organs in the body.
The team state that these bacteria are quite happy to live in the nose and it’s not in their interests to spread and kill their host. This is why they activate T regulatory cells, to keep the immune system in check and ensure their own survival. The findings suggest induction of T regulatory cell responses in the upper airways reduces the risk of inflammatory damage that could lead to bacterial invasion and the development of disease. Understanding this process can now lead us to investigate how the bacteria go from this state to causing lethal infections.
Vaccines are an essential part of the medical community’s fight against this disease and have been highly successful. However, they do not protect against all strains of pneumococci. Therefore, understanding the key immunological interactions with the pneumococcus, in the very first site they enter and colonise the human body is crucial to future development of better vaccines.
In this study the group have revealed how there is a delicate balance between the ability of the pneumococcus to colonise the host nasopharynx and the critical need of the immune system to prevent damaging inflammation in this key site. The team hope that this will lead to developing novel therapies based on modulating the host immune system to prevent subsequent invasive disease.
Source: Infection Control Today.
Michelle is a health industry veteran who taught and worked in the field before training as a science journalist.
Featured by numerous prestigious brands and publishers, she specializes in clinical trial innovation--expertise she gained while working in multiple positions within the private sector, the NHS, and Oxford University.